Navigation Links
Robert Haynes To Lead Licensing As VR Laboratories' Senior Vice President Product Introduction And Licensing

BONITA SPRINGS, Fla., Nov. 14, 2012 /PRNewswire-iReach/ -- VR Laboratories LLC today announced the appointment of Robert Haynes as Senior Vice President, Product Introduction and Licensing. Haynes brings more than 25 years of management and executive experience in pharmaceutical and biotechnology product development, partnering, and global commercialization.  Most recently, Haynes led the Alliance Management and New Product Planning departments at Human Genome Sciences (HGS). At HGS Haynes also led the development and global commercialization of the company's lead product - Benlysta®  - taking it from discovery through clinical development and successful commercialization around the world as the first new therapy approved for lupus in over 50 years. In addition to Benlysta Mr. Haynes has held leadership roles for numerous successful brands including Strattera®, Evista®, Axid®, Prozac®, and Ceclor®.


"Robert brings extensive experience in the pharmaceutical and biotechnology industries to VR and we look forward to his leadership in advancing our extensive pipeline internally and with partners across the globe," says Jeff Kottkamp, CEO of VR Laboratories. "As an innovative natural products company, we will benefit from his experience, developing, launching, commercializing, and partnering assets in all stages across many different therapeutic areas."

Haynes' background includes a wide variety of commercial management positions in both the pharmaceutical and biotechnology industries. This includes business development and licensing, strategic marketing, new product development, global brand and portfolio management, market research, and sales. He began his career with Eli Lilly and company in 1988 following receiving his Masters of Business Administration degree from the Owen Graduate School of Management at Vanderbilt University. In addition, he holds a Bachelors degree in Biological Science from DePauw University. 

"I look forward to continuing to develop and commercialize innovative medicines in the rapidly growing natural product industry," says Haynes. "VR Laboratories has great momentum as it looks to grow its business and expand its global presence. I'm excited to be joining VR's talented team and look forward to working with them to capitalize on their industry leading technology to build a successful fully integrated business."

About VR Laboratories

VR Laboratories is an innovative natural products company formed by industry professionals in 2010 to be the leading global formulator and producer of natural products.  VR Laboratories utilizes industry-changing proprietary technology to create, produce and market "First in Class" condition specific botanical based consumer health and wellness products, FDA-approved botanical pharmaceuticals and medicines and proprietary ingredients for medicinal and functional foods and beverages. The company utilizes a proprietary technology platform, which has fully developed more than 1,000 medicinal and functional ingredients.  VR Laboratories is headquartered in Bonita Springs, Florida.

SOURCE VR Laboratories
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
2. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Robert Farrell Joins Bionovos Board of Directors
5. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
6. LLSs Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
7. Sangui and SastoMed Complement Licensing Agreement in View of Increasing Sales Success
8. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
9. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
10. Aviir Diagnostic Laboratories Secures $8 Million In Funding From Silicon Valley Bank
11. Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
Post Your Comments:
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):